{"product_id":"abcam-ab237654","title":"Abcam, ab237654, anti-Rituximab ELISA Kit","description":"\u003cp\u003eSize: 96Test\u003cbr\u003e\nanti-Rituximab ELISA Kit is a Quantitative ELISA for the measurement of anti-Rituximab in Human in Biofluids samples.\u003cbr\u003e\nKey facts\u003cbr\u003e\nDetection method:Colorimetric,\u003cbr\u003e\nSample types:Plasma, Serum,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nAssay type:Quantitative,\u003cbr\u003e\nSensitivity:= 10 ng\/mL,\u003cbr\u003e\nRange:75 - 500 ng\/mL,\u003cbr\u003e\nAssay Platform:Microplate\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nanti-Rituximab ELISA Kit (ab237654) is designed to quantify\/measure the antibody against Rituximab with high specificity and sensitivity in biological matrices.\u003cbr\u003e\nThis product is manufactured by BioVision, an Abcam company and was previously called E4385 BioSim™ anti-Rituximab (Mabthera®) (Human) ELISA Kit. E4385-100 is the same size as the 96 test size of ab237654.\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nShipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nRituximab also known as anti-CD20 is a monoclonal antibody that targets the CD20 protein expressed on the surface of B cells. The CD20 protein is a non-glycosylated phosphoprotein with a mass of approximately 33 to 37 kilodaltons. It is expressed in both normal and malignant B cells from the pre-B-cell stage through the mature B-cell stage. The protein is absent in pro-B cells and plasma cells which helps in the specific targeting of B cells without affecting the stem cells or other immune cells.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nRituximab depletes B cells by inducing cell lysis through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab’s binding to CD20 leads to B cell apoptosis. As part of the immune system B cells produce antibodies; hence B cell depletion affects humoral immunity. However this depletion allows for the reduction of abnormal B cells in conditions like cancer and autoimmune diseases where aberrant B cell activity plays a harmful role.\u003cbr\u003e\nPathways\u003cbr\u003e\nCD20 does not belong to a multi-component signaling complex but plays a role in calcium signaling in B cells. It modulates calcium influx which is critical for B cell activation and regulation. The pathways involving CD20 are associated with B-cell receptor signaling an essential mechanism regulating B cell survival and proliferation. Other proteins like SYK and BLNK are involved in the extended signaling cascade triggered by B-cell receptor activation.\u003cbr\u003e\nRituximab plays an important role in the treatment of B-cell non-Hodgkin lymphomas and rheumatoid arthritis. It targets and removes malignant B cells in lymphoma offering an effective therapy alongside traditional chemotherapies. In rheumatoid arthritis rituximab reduces B cell-mediated inflammation and tissue damage. Rituximab's specificity for CD20 allows it to reduce disease-associated B cells without destroying all B cells minimizing unintended consequences on the immune system.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46843759198377,"sku":"ab237654","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/abcam-ab237654","provider":"Iright","version":"1.0","type":"link"}